Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes

Levemir®: the Physiological Basal Insulin. Documentation of Safety Aspects, Glycaemic Control and Weight

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01542463

Enrollment

4464

Registered

2012-03-02

Start date

2004-09-30

Completion date

2007-07-31

Last updated

2016-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

Brief summary

This study conducted in Europe. The aim of this study is to evaluated the use of insulin detemir (Levemir®) in insufficiently controlled patients with type 1 or type 2 diabetes.

Interventions

DRUGinsulin detemir

Prescribed at the discretion of the physician

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients with insufficiently controlled type 1 or type 2 diabetes mellitus under their previous therapy

Design outcomes

Primary

Measure	Time frame
HbA1c (glycaemic haemoglobin)	—
Fasting plasma glucose (FBG)	—

Secondary

Measure	Time frame
Body weight change	—
Adverse drug reactions (ADR)	—
Serious adverse drug reactions (SADR)	—
Hypoglycaemic episodes	—

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026